<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The B-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo>-2 (bcl-2) proto-oncogene is peculiar, as its product appears to provide survival advantage to B cells by blocking <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>Expression of bcl-2 protein was analyzed in 54 cases of primary non-Hodgkin's malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of the oral cavity by immunohistologic staining of paraffin-embedded tissue </plain></SENT>
<SENT sid="2" pm="."><plain>The immunophenotype of each <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was established with the use of a panel of monoclonal and polyclonal antibodies to lymphoid cell differentiation antigens </plain></SENT>
<SENT sid="3" pm="."><plain>The cases in the present study were 42 B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 7 T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and 5-<z:hpo ids='HP_0002665'>lymphomas</z:hpo> revealing histiocytic markers </plain></SENT>
<SENT sid="4" pm="."><plain>Sixteen of the 42 B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were positive for bcl-2 protein, and were composed of 7 low-grade B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and 9 high-grade B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Seven low-grade B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were composed of one mucosa-associated lymphoid tissue type, three centrocytic types and three <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e>-centrocytic types </plain></SENT>
<SENT sid="6" pm="."><plain>Nine high-grade B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> comprised four <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> types, one <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> type and four lymphoblastic types </plain></SENT>
<SENT sid="7" pm="."><plain>Enhanced expression of the bcl-2 oncogenic protein was detectable in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells in 2 cases for the T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and one case for the true histiocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast to the previous reports of American node-based <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, Japanese primary oral <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in our series expressed a lower frequency of bcl-2 protein </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, the present study indicated that bcl-2 protein was expressed on a wide variety of B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and true histiocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and that differences in bcl-2 protein expression may be useful in the diagnostic separation of lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with B-cell marker from Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>